ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
And the company might one day follow Galapagos into decentralised manufacturing.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
